ex-ghost
Footballguy
And here it is, Fueurstein hit piece: https://www.statnews.com/2020/07/31/cytodyn-leronlimab-covid19-pourhassan-call/
Fantasy Football - Footballguys Forums
This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
***OFFICIAL CYDY/Leronlimab Thread*** (3 Viewers)
- Thread starter This_Guy
- Start date
Jayrok
Footballguy
Jayrok
Footballguy
bshell27
Footballguy
Didn't he have to wait until today as there was a 10% loss Wednesday?Was there any doubt?
Dwayne Hoover
Footballguy
There should be plenty of buyers today if it drifts lower.
Jayrok
Footballguy
Seems the surge at the EOD on Wednesday brought them under the 10% loss.
He had an article ready for a response to the call. A template. He just filled in the gaps last night or early this AM. They have to take advantage of any type of release from Cytodyn (PR or conf call). One day they'll move on to another group of targets in their sandbox.
SouthJersey
Footballguy
Any melting yet?
Dwayne Hoover
Footballguy
I got more at 4.89 myselfin for 1100 more shares at 4.89. was making coffee and couldn't get lower
arrow1
Footballguy
Polish Hammer
made of glass
This is just based on my experience from selling to doctors with clinical info. The primary endpoint stated day 14 as the point in timeline to be evaluated. It doesn't matter if they are better at day 3. If by day 14 the placebo caught up with effectiveness (or just closed the gap on significance) many docs won't read deep enough to even learn that. They'll label it a failed trial. Also, "clinical improvement" does not equal "statistical significance." Not sure if they'll run KM curves on this data, but if they do what matters is where they end. It's like saying that the Falcons were really beating the Pats in the Super Bowl, just not at the end.
As an example, at one time I managed in a company where a product had a trial where the primary endpoint was "trending towards significance" (meaning it didn't achieve proper p-value, but did show consistent improvement versus standard of care). Then on a secondary endpoint - which is traditionally "more important" than the primary - we did hit statistical significance. If that had actually been our primary endpoint it would have meant shiploads of new orders. But because the primary didn't meet significance our business lost a large percentage almost overnight. Took better part of 2 years to recover.
Again, it wasn't for a pandemic problem type of solution, but I can only speak to what I know. I'm not going to make crap up on this stuff just to take a stand. Just want to give folks my perspective.
Capella
Footballguy
But if it improved at day 3 maybe the negative effects that typically come by day 14 won’t be there? I have no idea, just spitballing.
Last edited by a moderator:
HugeUpside
Footballguy
Tried getting 2,000 more at 4.78 and got nothing. Boo
Jayrok
Footballguy
Thanks for your perspective and knowledge of the process. I do think that present circumstances may have a bearing on outcome or at least have an impact on what the FDA will do. These aren't typical times. But who knows?
adonis
Footballguy
Well...lucky me. Got back in at 4.75 this morning back to my 100% position at a lower overall PPS.
I'm going to just guess, wildly, that the sell-offs the past few days in the AM have been that company who did the loan selling off huge chunks of their position. Because the bounce back is just too quick and durable.
Thanks. Just tried to set one for the 1000 extra shares that I just bought but TD says that they do not allow trailing stop orders for OTC stocks. Hopefully will only be an issue with CYDY for a few more weeks.
adonis
Footballguy
Would it be correct to assume that the endpoints the physicians were monitoring were for phase 3 trials, rather than phase 2 trials?
Don't Noonan
Footballguy
I am looking to add at $4.80, not sure if it makes it back there again today. Might have to raise my limit order.
adonis
Footballguy
Don Hutson
Footballguy
CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure
https://www.statnews.com/2020/07/31/cytodyn-leronlimab-covid19-pourhassan-call/
CytoDyn CEO Nader Pourhassan used a conference call on Thursday evening to claim success with the company’s experimental Covid-19 drug — but his description of the clinical data, if true, suggests the drug didn’t meet the study’s primary goal.
In disjointed comments to investors, Pourhassan insisted that leronlimab delivered “positive efficacy results” in the Covid-19 study. CytoDyn intended to quickly submit the “strong results” to the Food and Drug Administration and expected to win approval for leronlimab as a new treatment for Covid-19, he added.
But in describing the leronlimab data, Pourhassan only said the drug improved symptoms after three days, not the 14 days set as the study’s endpoint. If that’s the case, it would suggest the 75-person trial failed to achieve its primary goal. Generally, the FDA does not approve drugs which cannot prove a benefit for patients, even those with Covid-19.
In another unusual departure from normal disclosure, CytoDyn provided no documentation, whether by press release or SEC filing, to back up the statements made by Pourhassan on Thursday evening’s conference call.
Since early July, CytoDyn has promised to disclose the full results from the clinical trial it calls CD-10, which is investigating weekly injections of leronlimab, a repurposed and still-experimental HIV drug, to treat Covid-19. But those data are still missing.
On July 21, CytoDyn issued a press release claiming “impressive” safety data from the CD-10 study, while also disclosing the death of a Covid-19 patient following treatment with leronlimab. The company said the death was unrelated to its drug, but declined to offer any corroborating details.
CytoDyn’s Phase 2 study enrolled patients with mild to moderate symptoms of Covid-19 without need for oxygen support. Hospitalization was not an eligibility requirement, unlike other studies involving Covid-19 patients with moderate disease like Gilead Sciences’ remdesivir.
The primary efficacy goal of the study measured “clinical improvement” across four symptoms — fever, muscle ache, shortness of breath, and cough — after 14 days of treatment, according to a description of the study on the U.S. government’s ClinicalTrials.gov website.
This is a relatively weak and imprecise way to measure the benefit of a drug for Covid-19. Among the four symptoms, fever can be measured most objectively, but fever reduction alone has not been considered a clinically meaningful primary endpoint in any other Covid-19 clinical trial. Gilead’s remdesivir study in moderate Covid-19 patients, by comparison, defined clinical improvement based on a scale that assessed death, intubation, use of supplemental oxygen and hospitalization status.
CytoDyn set the efficacy bar for leronlimab’s study so low that even a positive outcome versus placebo would have been considered medically irrelevant.
On Thursday’s conference call, Pourhassan claimed leronlimab achieved the primary efficacy goal of the study. “We have seen improvement in day 3 vs. day zero in the leronlimab arm as compared to the placebo arm,” he said.
But this is not the primary efficacy goal of the study, which is required to show a statistically significant clinical improvement at day 14. Pourhassan also didn’t indicate if the comparison of leronlimab and placebo was statistically significant after three days.
Similarly, Pourhassan described two secondary efficacy goals of the study where leronlimab “beat” placebo. But the study lists 16 different secondary outcomes, which raises questions about whether leronlimab failed all the others.
From the earliest days of the coronavirus epidemic, Pourhassan has been unabashedly promotional about leronlimab and its potential to treat and save the lives of patients with Covid-19. In May, Pourhassan told investors that “you may sue us, hate us, or short our stock, but you can never deny that leronlimab is most likely saving some patients from the plague of coronavirus.”
The tactics have been effective. CytoDyn’s market value now tops $3 billion, despite being a penny stock that trades over the counter. Pourhassan and CytoDyn Chairman Scott Kelly have both personally profited from these promotional efforts, selling company shares for $12 million and $3 million, respectively. Pourhassan has previously said he sold his company stock to pay for manufacturing of the drug and avoid delays.
But time and again, statements made by CytoDyn and Pourhassan turn out to be false or misleading.
In late June, CytoDyn said it had reached an agreement with the “NIH of Mexico” to conduct a clinical trial of leronlimab in Covid-19 patients. “Leronlimab could receive approval in Mexico very quickly,” Pourhassan said at the time.
Asked for an update on the Mexico clinical trial during Thursday’s call, Pourhassan said it was on hold. Similarly, a clinical combining leronlimab and remdesivir, which CytoDyn said in May would be starting soon, has also been shelved.
Pourhassan further claimed on Thursday that the FDA might approve leronlimab for Covid-19 based on safety data alone, even if the efficacy results showed no benefit for patients. To support this statement, Pourhassan cited Regeneron Pharmaceuticals, which he said had altered its own Covid-19 clinical trials to use safety and not efficacy as the primary outcome goals.
Regeneron is conducting five clinical trials of experimental antibody treatments for Covid-19, none of which will rely solely on safety data as their primary goals, according to ClinicalTrials.gov.
CytoDyn pitches leronlimab to investors as a wonder-drug with the potential to cure patients with HIV, Covid-19, multiple types of cancer, the fatty liver disease known as NASH, Alzheimer’s disease, multiple sclerosis, and graft-versus-host disease.
But in almost all these diseases, promised clinical trials of leronlimab have failed to materialize. On Thursday’s call, for instance, Pourhassan said the first NASH patient would be injected with leronlimab in September, yet there is no independent listing for a NASH clinical trial involving leronlimab.
Two weeks ago, the FDA refused to accept an application from CytoDyn seeking the approval of leronlimab to treat patients with HIV. The company is scheduled to meet with FDA officials next week in an attempt to get the HIV submission back on track, Pourhassan said.
https://www.statnews.com/2020/07/31/cytodyn-leronlimab-covid19-pourhassan-call/
CytoDyn CEO Nader Pourhassan used a conference call on Thursday evening to claim success with the company’s experimental Covid-19 drug — but his description of the clinical data, if true, suggests the drug didn’t meet the study’s primary goal.
In disjointed comments to investors, Pourhassan insisted that leronlimab delivered “positive efficacy results” in the Covid-19 study. CytoDyn intended to quickly submit the “strong results” to the Food and Drug Administration and expected to win approval for leronlimab as a new treatment for Covid-19, he added.
But in describing the leronlimab data, Pourhassan only said the drug improved symptoms after three days, not the 14 days set as the study’s endpoint. If that’s the case, it would suggest the 75-person trial failed to achieve its primary goal. Generally, the FDA does not approve drugs which cannot prove a benefit for patients, even those with Covid-19.
In another unusual departure from normal disclosure, CytoDyn provided no documentation, whether by press release or SEC filing, to back up the statements made by Pourhassan on Thursday evening’s conference call.
Since early July, CytoDyn has promised to disclose the full results from the clinical trial it calls CD-10, which is investigating weekly injections of leronlimab, a repurposed and still-experimental HIV drug, to treat Covid-19. But those data are still missing.
On July 21, CytoDyn issued a press release claiming “impressive” safety data from the CD-10 study, while also disclosing the death of a Covid-19 patient following treatment with leronlimab. The company said the death was unrelated to its drug, but declined to offer any corroborating details.
CytoDyn’s Phase 2 study enrolled patients with mild to moderate symptoms of Covid-19 without need for oxygen support. Hospitalization was not an eligibility requirement, unlike other studies involving Covid-19 patients with moderate disease like Gilead Sciences’ remdesivir.
The primary efficacy goal of the study measured “clinical improvement” across four symptoms — fever, muscle ache, shortness of breath, and cough — after 14 days of treatment, according to a description of the study on the U.S. government’s ClinicalTrials.gov website.
This is a relatively weak and imprecise way to measure the benefit of a drug for Covid-19. Among the four symptoms, fever can be measured most objectively, but fever reduction alone has not been considered a clinically meaningful primary endpoint in any other Covid-19 clinical trial. Gilead’s remdesivir study in moderate Covid-19 patients, by comparison, defined clinical improvement based on a scale that assessed death, intubation, use of supplemental oxygen and hospitalization status.
CytoDyn set the efficacy bar for leronlimab’s study so low that even a positive outcome versus placebo would have been considered medically irrelevant.
On Thursday’s conference call, Pourhassan claimed leronlimab achieved the primary efficacy goal of the study. “We have seen improvement in day 3 vs. day zero in the leronlimab arm as compared to the placebo arm,” he said.
But this is not the primary efficacy goal of the study, which is required to show a statistically significant clinical improvement at day 14. Pourhassan also didn’t indicate if the comparison of leronlimab and placebo was statistically significant after three days.
Similarly, Pourhassan described two secondary efficacy goals of the study where leronlimab “beat” placebo. But the study lists 16 different secondary outcomes, which raises questions about whether leronlimab failed all the others.
From the earliest days of the coronavirus epidemic, Pourhassan has been unabashedly promotional about leronlimab and its potential to treat and save the lives of patients with Covid-19. In May, Pourhassan told investors that “you may sue us, hate us, or short our stock, but you can never deny that leronlimab is most likely saving some patients from the plague of coronavirus.”
The tactics have been effective. CytoDyn’s market value now tops $3 billion, despite being a penny stock that trades over the counter. Pourhassan and CytoDyn Chairman Scott Kelly have both personally profited from these promotional efforts, selling company shares for $12 million and $3 million, respectively. Pourhassan has previously said he sold his company stock to pay for manufacturing of the drug and avoid delays.
But time and again, statements made by CytoDyn and Pourhassan turn out to be false or misleading.
In late June, CytoDyn said it had reached an agreement with the “NIH of Mexico” to conduct a clinical trial of leronlimab in Covid-19 patients. “Leronlimab could receive approval in Mexico very quickly,” Pourhassan said at the time.
Asked for an update on the Mexico clinical trial during Thursday’s call, Pourhassan said it was on hold. Similarly, a clinical combining leronlimab and remdesivir, which CytoDyn said in May would be starting soon, has also been shelved.
Pourhassan further claimed on Thursday that the FDA might approve leronlimab for Covid-19 based on safety data alone, even if the efficacy results showed no benefit for patients. To support this statement, Pourhassan cited Regeneron Pharmaceuticals, which he said had altered its own Covid-19 clinical trials to use safety and not efficacy as the primary outcome goals.
Regeneron is conducting five clinical trials of experimental antibody treatments for Covid-19, none of which will rely solely on safety data as their primary goals, according to ClinicalTrials.gov.
CytoDyn pitches leronlimab to investors as a wonder-drug with the potential to cure patients with HIV, Covid-19, multiple types of cancer, the fatty liver disease known as NASH, Alzheimer’s disease, multiple sclerosis, and graft-versus-host disease.
But in almost all these diseases, promised clinical trials of leronlimab have failed to materialize. On Thursday’s call, for instance, Pourhassan said the first NASH patient would be injected with leronlimab in September, yet there is no independent listing for a NASH clinical trial involving leronlimab.
Two weeks ago, the FDA refused to accept an application from CytoDyn seeking the approval of leronlimab to treat patients with HIV. The company is scheduled to meet with FDA officials next week in an attempt to get the HIV submission back on track, Pourhassan said.
CGRdrJoe
Footballguy
wtf? Easy racistWhats funny is that I'm sure the cydy clowns are complaining to each other about how the market doesn't understand how great what they are seeing is. Speak english in complete sentences!
Dwayne Hoover
Footballguy
I don't like this guy, especially since I've seen him completely lie in the past. That being said, this article summed up the short argument as good as you can. He got his confirmation bias from the call yesterday and is running with it. This article doesn't seem over the top if that's what you believe.
It is odd that he has gone all in multiple times when he doesn't have all the data either. Seems like he's risking some kind of rep here by constantly digging into an unknown endpoint but maybe it will be completely forgotten when he exposes a different fraud later. There are no shortage of frauds in this industry.
Last edited by a moderator:
djmich
Footballguy
Not sure if this is
but when the first comments from the subsequent short article are "disjointed comments to investors" and cydy forums across the planet are trying to interpret what they said ...its pretty clear they do not know how to communicate.
CGRdrJoe
Footballguy
I thought you meant that towards NPNot sure if this is
adonis
Footballguy
Agreed. His article this time was pretty well done. Stayed close to facts, didn't require lying to make a point, and raised some reasonable questions about the reliability of NP, lack of results, etc.
Certainly reasonable to ask many of the questions raised in the article.
Polish Hammer
made of glass
If you are talking about my anecdote about our "failed trial" in the past, the answer is not exactly. The product was already approved by the FDA and in the market for a while. Clinical trials don't really stop on many drugs/devices once FDA approval is in place. Just because something is approved doesn't mean every doc writes for it, or even those that do write for it do so for every indication. I genuinely can't speak to how the FDA is going to respond to endpoints for phase 2 vs phase 3 - my answers have always been geared to how I think clinicians practicing in the hospitals would respond to the data.
⚡DEADHEAD⚡
Footballguy
I don't see it the same way. There's all sorts of word-bending taking place. For example, "But in describing the leronlimab data, Pourhassan only said the drug improved symptoms after three days, not the 14 days set as the study’s endpoint. If that’s the case, it would suggest the 75-person trial failed to achieve its primary goal. Generally, the FDA does not approve drugs which cannot prove a benefit for patients, even those with Covid-19."
This was a point Lalezari made to describe a surprise benefit, something he saw occurring sooner than anticipated.
djmich
Footballguy
Well, I did mean them towards the entire cydy team, NP is the lead.I thought you meant that towards NP
I've defended NP a lot of times here in terms of everything he's accomplished to bring this company to where it is today. Some folks throw that away almost as luck, I think its incredible and admirable.
That does not change the fact that him and his organization are doing a monumentally poor job communicating. I could give two ####s about his accent if thats what you think I was referring to, I give many ####s about the fact that they cannot communicate completely and clearly.
Does NP's command of the language get in the way, I don't think so but I also t think at best it is not helping. Here's an example, they literally have to re-issue PR's because the sentence structure is incorrect....its missing words! I'm not even saying its missing a medical term or incomplete its missing basic words. And then from yesterdays call we are all trying to figure out what the #### this guy actually told us because he cannot or refuses to provide complete information in a sentence structure that is understandable by investors.
I'll end with these guys talk with an excitement like "they have the nuts" and literally every time they open their mouths the stock goes down. Either they are charlatans or can't communicate.
Last edited by a moderator:
Bluto Blutarsky
Footballguy
Exactly the way I took it, too. They figured they’d see the results on day 14 because they’ve already had luck with severe patients. Getting good results that early was a surprise benefit. This is also what Dr. Patterson said on Dr. Been. It would be a HUGE advantage in dealing with Covid if we can prevent people from being m/m and deteriorating into s/c.
djmich
Footballguy
If only there was a forum, i dunno like an investor call, where they could have communicated this more clearly.
Dwayne Hoover
Footballguy
I get what you guys are saying and hope you are right but there were gaps into what was communicated. Feuerstein just tears into the gaps and uses it for his own confirmation bias.
At the end of the day, we are all scrambling to interpret this the best way that we can. I'm still not clear even though I keep buying in on dips. It seems like a good gamble. Helps that Chet has advocated for this and has been spot on so far and also helps that you have doctors with really good credentials in the corner (whether they have a business interest or not)
Don Hutson
Footballguy
We might have to accept that leronlimab isn't a magical monotherapy for Covid. It is a mild drug so it makes sense that its effects wouldn't be dramatic. But it could still be used in a cocktail since it has zero negative side effects and probably marginally helps. Also, Patterson put a lot of emphasis in his last interview that leronlimab would be the perfect drug to stockpile for unknown future medical conditions. When no drug has been developed, using an anti-inflammatory like leronlimab can provide assistance when nothing else is known to work. The list of 64 indications is a bit ridiculous but it might literally help in every situation since it is a general anti-inflammatory which helps level the playing field so that the immune system can be more effective no matter what the ailment.
I also haven't given up on the S/C trial. There is a ton of anecdotal evidence from the 60+ eINDs that indicate that it works in the worst cases. Patterson has even on multiple occasions implied that he knows which patients in the S/C trial are getting leronlimab and which are getting the placebo and that the treatment arm is faring much better. He probably shouldn't be testing to determine which samples have leronlimab and he certainly shouldn't be telling us that he has that information. But hopefully, it is true and Patterson isn't just looking for one last big payday at the ripe old age of 57.
Lastly, it not being a magical potion for Covid doesn't take away from its potential with Cancer and HIV. Cancer and HIV are slow developing conditions where maybe the patient's immune system just needs a little help by creating a better environment to work. Modern medicine now knows the importance of inflammation in virtually every condition. Covid comes on very fast and might need something that is stronger. The lack of results in the M2M trial is frustrating but it's not the end of story.
I also haven't given up on the S/C trial. There is a ton of anecdotal evidence from the 60+ eINDs that indicate that it works in the worst cases. Patterson has even on multiple occasions implied that he knows which patients in the S/C trial are getting leronlimab and which are getting the placebo and that the treatment arm is faring much better. He probably shouldn't be testing to determine which samples have leronlimab and he certainly shouldn't be telling us that he has that information. But hopefully, it is true and Patterson isn't just looking for one last big payday at the ripe old age of 57.
Lastly, it not being a magical potion for Covid doesn't take away from its potential with Cancer and HIV. Cancer and HIV are slow developing conditions where maybe the patient's immune system just needs a little help by creating a better environment to work. Modern medicine now knows the importance of inflammation in virtually every condition. Covid comes on very fast and might need something that is stronger. The lack of results in the M2M trial is frustrating but it's not the end of story.
Last edited by a moderator:
djmich
Footballguy
Nader: I'm so excited to share my excitement about these exciting results. I am pleased to announce that we have seen positive results in one of our endpoints. I don't have the topline results for the other endpoints, nobody has seen them, but I can tell you they are good. In addition, I observed one of the patients eyelid move while in a coma and that was incredible. Eyelids don't move in ECMO! And I'd just like to say that I wish all the evil shorters would stop being mean and understand how great this data that I have shared with you is.McBokonon said:
Last edited by a moderator:
JerseyToughGuys
Tough Guy
You would think we would be desensitized to delay at this point.
adonis
Footballguy
Makes sense. I'm just under the impression (asking for input in case it's false) that most clinicians are responding to phase 3 trials as those are the ones that guide clinical decision more often than phase 2 results. Phase 2 results, again maybe I have this wrong, are often used to figure out safety and how effective the drug is in various areas. That's why I think treating primary endpoints and secondary endpoints in phase 2 trials as the same as in phase 3 trials isn't necessarily fair.Polish Hammer said:
If the phase 2 trial shows promise on the primary but doesn't hit "significance" but quite a few meaningful secondary endpoints show "significance" and are beneficial for the patients, that would likely lead to a phase 3 trial focusing more on those areas in which significance was shown, with a shift in how the phase 3 primary endpoint was geared.
In the phase 2 trial we have here for m/m, it was initiated with collaboration from the FDA to highlight what they thought early on would be the most significant data points, and they included a slew of meaningful secondary endpoints as well to make sure they were capturing how effective the drug was, if at all. If it turns out the primary endpoint wasn't a good choice, but a fair number of secondary endpoints that are relevant and important to clinical improvement for patients, the results won't be dismissed just because they didn't hit their primary endpoint. This trial was a scattershot of endpoints to judge efficacy of leronlimab. Its efficacy doesn't rely solely on the primary endpoint, in other words, but in the bigger picture of how the drug can help people.
If the secondary endpoints that are significant can be presented in such a way to show that clinical benefit can be offered by using the drug, it'd be foolish for anyone to dismiss the trial based on the primary endpoint missing "significance", if the secondary endpoints show statistically significant efficacy in areas that are important for patient wellbeing.
All this said, i'm not really arguing with you...just making points that are up for refutation by anyone. Looking for feedback on these views.
⚡DEADHEAD⚡
Footballguy
He's not a very bright guy. Still fascinates me that he's the CEO. I don't think he became that on merit.
Jayrok
Footballguy
I see the same thing. And this comment you quoted is basically the only new piece of ammo that AF is using in the article. NP promised an update. He gave an update. He didn't provide all efficacy detailed data. That is coming, he said, in "10 days or so."⚡DEADHEAD⚡ said:
So the 14 day endpoint data will be discussed in detail in the report coming in 10 days or so.
So this was just an update and Lelazari commented because it was a surprise and they thought it noteworthy that patients on LL were showing improved symptoms in only 3 days.
AF is confusing this update with all efficacy results in the trial and he is suggesting that NP and his staff are purposely dodging endpoints because they know the results are bad news. It's ridiculous.
That said, I think that NP, while giving "updates", should stick to those that are associated with exact endpoints. Because everything else, no matter how positive, will be used against him in a hit piece. Absurd.
adonis
Footballguy
NP embellishes. He's not in control of his public messaging. He's an effective excitement machine, but his promises have fallen through repeatedly, and you can't count on his word in terms of deadlines or the precision of facts he's saying he's stating. It's a risk you run believing him.djmich said:Well, I did mean them towards the entire cydy team, NP is the lead.
I've defended NP a lot of times here in terms of everything he's accomplished to bring this company to where it is today. Some folks throw that away almost as luck, I think its incredible and admirable.
That does not change the fact that him and his organization are doing a monumentally poor job communicating. I could give two ####s about his accent if thats what you think I was referring to, I give many ####s about the fact that they cannot communicate completely and clearly.
Does NP's command of the language get in the way, I don't think so but I also t think at best it is not helping. Here's an example, they literally have to re-issue PR's because the sentence structure is incorrect....its missing words! I'm not even saying its missing a medical term or incomplete its missing basic words. And then from yesterdays call we are all trying to figure out what the #### this guy actually told us because he cannot or refuses to provide complete information in a sentence structure that is understandable by investors.
I'll end with these guys talk with an excitement like "they have the nuts" and literally every time they open their mouths the stock goes down. Either they are charlatans or can't communicate.
There is also the other set of interests involved, which are the folks like AF, who truly can make money by capitalizing on the lack of delivery from NP, and the lack of precision in his comments, and the lack of released data. So it's not just NP's poor communication and embellishments, but there's an active counter-party out there seeking to profit literally from this vagueness and lack of concrete data.
It's a balancing act that they both benefit from in ways, and suffer from. NP benefits because the stock price has been driven by excitement and potential based off anecdotes, preliminary data, BP and others support, but at the same time it opens him to attacks from AF and others who can capitalize on his lack of precision and tendency to exaggerate or make promises he doesn't deliver on. NP benefits from this part of his nature, but he also suffers as shorters and decreased stock price and folks not taking him at his word have the opposite effects on the stock than he'd expect.
SouthJersey
Footballguy
Has $CYDY tested Leronlimab as a weight loss drug? I'm getting fat eating snacks all day while refreshing the stock price.
